Australia markets open in 2 hours 51 minutes

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.52-0.07 (-1.06%)
At close: 04:00PM EDT
6.52 0.00 (0.00%)
After hours: 04:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 872.09M
Enterprise value 175.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)31.62
Price/book (mrq)1.16
Enterprise value/revenue 6.87
Enterprise value/EBITDA -0.47

Trading information

Stock price history

Beta (5Y monthly) 1.63
52-week change 3-36.88%
S&P500 52-week change 324.19%
52-week high 313.32
52-week low 35.70
50-day moving average 38.20
200-day moving average 39.24

Share statistics

Avg vol (3-month) 31.22M
Avg vol (10-day) 31.51M
Shares outstanding 5132.34M
Implied shares outstanding 6132.34M
Float 893.34M
% held by insiders 13.46%
% held by institutions 198.33%
Shares short (15 Apr 2024) 410.69M
Short ratio (15 Apr 2024) 48.34
Short % of float (15 Apr 2024) 410.39%
Short % of shares outstanding (15 Apr 2024) 48.08%
Shares short (prior month 15 Mar 2024) 411.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)9,426,300.00%

Management effectiveness

Return on assets (ttm)-24.40%
Return on equity (ttm)-40.18%

Income statement

Revenue (ttm)25.55M
Revenue per share (ttm)0.21
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -374.15M
Net income avi to common (ttm)-341.97M
Diluted EPS (ttm)-2.79
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)750.09M
Total cash per share (mrq)5.72
Total debt (mrq)53.47M
Total debt/equity (mrq)7.11%
Current ratio (mrq)25.44
Book value per share (mrq)5.90

Cash flow statement

Operating cash flow (ttm)-300.32M
Levered free cash flow (ttm)-183.52M